Anti-IFNLR1 antibody produced in rabbit
SIGMA/HPA017319 - Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Synonym: Anti-CRF2-12; Anti-Cytokine receptor class-II member 12; Anti-Cytokine receptor family 2 member 12; Anti-IFN-lambda R1; Anti-IL-28R-alpha; Anti-IL-28RA; Anti-IL28RA; Anti-Interferon lambda receptor 1; Anti-Interleukin-28 receptor alpha chain precursor; Anti-Likely interleukin or cytokine receptor 2
Product Type: Chemical
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| conjugate | unconjugated |
| form | buffered aqueous glycerol solution |
| immunogen sequence | FEVEPAPPVLVLTQTEEILSANATY |
| product line | Prestige Antibodies® Powered by Atlas Antibodies |
| Quality Level | 100 ![]() |
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunofluorescence: 0.25-2 μg/mL |
| immunohistochemistry: 1:50-1:200 |
| Application: | Anti-IL28RA antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project ![]() and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige . |
| Biochem/physiol Actions: | IFNLR1 (Interferon λ receptor 1) functions as a component of IFN-λ protein. It forms a ligand-receptor system upon binding to interferon-λ1. It actively participates in the JAK-STAT (Janus kinases-signal transducers and activators of transcription) pathway. It has been suggested that IFNLR1 polymorphism can be an effective tool for identifying early treatment failure of early hepatitis C virus (HCV) 2 treatment. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| Features and Benefits: | Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section. Every Prestige Antibody is tested in the following ways: • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues. • Protein array of 364 human recombinant protein fragments. |
| General description: | IFNLR1 (Interferon λ receptor 1) is an orphan class II receptor chain belonging to the heterodimeric class II cytokine receptor. It is widely expressed in human cell lines and tissues. |
| Immunogen: | Interleukin-28 receptor alpha chain precursor recombinant protein epitope signature tag (PrEST) |
| Legal Information: | Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Other Notes: | Corresponding Antigen APREST72355 |
| Physical form: | Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |

